Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Advocate Health embraces drone technology for faster patient service

31

Mar 2026

Advocate Health embraces drone technology for faster patient service

Advocate Health announced Thursday it will launch the nation's largest hospital-based drone delivery network, transforming how many of its patients receive prescriptions and home health supplies, while also reducing turnaround time for lab results, which are vital to timely diagnosis and treatment.

Polygenic embryo testing raises ethical concerns beyond disease prevention

31

Mar 2026

Polygenic embryo testing raises ethical concerns beyond disease prevention

For more than four decades, in vitro fertilization (IVF) has helped families have children. Scientists estimate that more than 10 million people worldwide have been born through IVF and related assisted reproductive technologies, according to the International Committee for Monitoring Assisted Reproductive Technologies.

How could bisphenol A raise depression risk? Study identifies six key molecular targets

31

Mar 2026

How could bisphenol A raise depression risk? Study identifies six key molecular targets

An integrative Translational Psychiatry study linked BPA exposure to major depressive disorder by identifying 571 shared targets and six core genes, with genetic, transcriptomic, docking, and mouse-model data supporting plausible mechanistic pathways. The strongest signals pointed to AKT1, SRC, PLCG2, and JAK3 as potential contributors, while EGFR appeared protective.

How vitamin D in the first 1,000 days may shape lifelong health

31

Mar 2026

How vitamin D in the first 1,000 days may shape lifelong health

This narrative review argues that vitamin D is clearly important for skeletal health during the first 1,000 days of life and may also shape immune, metabolic, and selected neurodevelopmental pathways during early development. However, the authors stress that human evidence for most non-skeletal outcomes remains heterogeneous, with benefits appearing most consistent in populations with baseline deficiency.

What happens when more of your exercise is vigorous instead of moderate?

31

Mar 2026

What happens when more of your exercise is vigorous instead of moderate?

In a large UK Biobank analysis, a higher proportion of vigorous physical activity relative to total activity volume was associated with lower risks of eight major chronic diseases and all-cause mortality, even after accounting for overall activity volume. Device-based data suggested that activity intensity generally offered greater preventive potential than total volume alone across most outcomes.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.